Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Purpose
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Conditions
- Glioblastoma
- Gliosarcoma
Eligibility
- Eligible Ages
- Between 18 Years and 70 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- STEP 1 REGISTRATION: No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered) - STEP 1 REGISTRATION: Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin and eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 30. If tissue cannot be received by postoperative calendar day 30, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 8 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be completed within 10 business days of receipt of tissue. Results will be entered by the central lab directly into Rave. Note: In the event of an additional tumor resection(s), tissue must be received within 30 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection is required; stereotactic biopsy alone is not allowed because it will not provide sufficient tissue for MGMT analysis - STEP 1 REGISTRATION: Willing to use highly effective method of contraception for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 6 months after completing treatment; this inclusion is necessary because the treatment in this study may be significantly teratogenic - STEP 1 REGISTRATION: The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information - STEP 2 REGISTRATION: Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review - STEP 2 REGISTRATION: MGMT promoter with methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or unmethylated MGMT promoter are excluded - Note: Any MGMT result other than methylated would require step 2 registration to be reported as a "central review failure" - STEP 2 REGISTRATION: Contrast-enhanced brain MRI performed either after surgery or prior to step 2 registration - STEP 2 REGISTRATION: IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.) - STEP 2 REGISTRATION: History/physical examination within 28 days prior to step 2 registration - STEP 2 REGISTRATION: Karnofsky performance status (KPS) >= 70 within 28 days prior to step 2 registration - STEP 2 REGISTRATION: Neurologic function assessment within 28 days prior to step 2 registration - STEP 2 REGISTRATION: Age 18-70 years - STEP 2 REGISTRATION: Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Leukocytes >= 2,000/mm^3 (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Absolute neutrophil count >= 1,500/mm^3 (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Platelets >= 100,000/mm^3 (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (Within 14 days prior to step 2 registration) - STEP 2 REGISTRATION: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B) - STEP 2 REGISTRATION: For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load - Note: Known positive test for hepatitis C virus ribonucleic acid (HCV ribonucleic acid [RNA]) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy - STEP 2 REGISTRATION: Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to step 2 registration are eligible for this trial. Testing is not required for entry into protocol - STEP 2 REGISTRATION: Negative serum or urine pregnancy test (in persons of childbearing potential) within 14 days prior to step 2 registration - Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
Exclusion Criteria
- STEP 2 REGISTRATION: Prior therapy for tumor except for resection or prior laser interstitial thermal therapy (LITT). For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is Gliadel wafer, radiotherapy, radiosurgery, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery - Note: 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent. Prior laser interstitial thermal therapy (LITT) is allowed - STEP 2 REGISTRATION: Current or planned treatment with any other investigational agents for the study cancer - STEP 2 REGISTRATION: Definitive clinical or radiologic evidence of metastatic disease outside the brain - STEP 2 REGISTRATION: Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years - STEP 2 REGISTRATION: Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields - STEP 2 REGISTRATION: Pregnancy and individuals unwilling to discontinue nursing due to the potential teratogenic effects and potential risk for adverse events in nursing infants - STEP 2 REGISTRATION: History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or lomustine - STEP 2 REGISTRATION: History of pulmonary fibrosis - STEP 2 REGISTRATION: Uncontrolled intercurrent illness including, but not limited to: - Ongoing or active infection requiring intravenous (IV) antibiotics, IV antiviral, or IV antifungal treatment - Symptomatic congestive heart failure, defined as New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification) - Unstable angina pectoris within 6 months prior to Step 2 registration - Uncontrolled cardiac arrhythmia - Psychiatric illness/social situations that would limit compliance with study requirements - STEP 2 REGISTRATION: No evidence of diffuse leptomeningeal disease that requires whole brain irradiation
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (radiation therapy, temozolomide) |
Patients undergo radiation therapy 5 days per week and receive temozolomide PO QD for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial. |
|
Experimental ARM II (radiation therapy, temozolomide, lomustine) |
Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 of each cycle and temozolomide PO QD on days 2-6 of each cycle. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial. |
|
Recruiting Locations
Fairbanks 5861897, Alaska 5879092 99701
Fayetteville 4110486, Arkansas 4099753 72703
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Rogers 4128894, Arkansas 4099753 72758
Springdale 4132093, Arkansas 4099753 72762
Anaheim 5323810, California 5332921 92806
Antioch 5324200, California 5332921 94531
Auburn 5325223, California 5332921 95602
Auburn 5325223, California 5332921 95603
Bellflower 5327422, California 5332921 90706
Berkeley 5327684, California 5332921 94704
Carmichael 5334336, California 5332921 95608
Carmichael 5334336, California 5332921 95608
Duarte 5344147, California 5332921 91010
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Elk Grove 5346111, California 5332921 95758
Fremont 5350734, California 5332921 94538
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Fresno 5350937, California 5332921 93720
Irvine 5359777, California 5332921 92612
Los Angeles 5368361, California 5332921 90027
Modesto 5373900, California 5332921 95356
Mountain View 5375480, California 5332921 94040
Oakland 5378538, California 5332921 94611
Oakland 5378538, California 5332921 94611
Ontario 5379439, California 5332921 91761
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94301
Rancho Cordova 5385941, California 5332921 95670
Redwood City 5386834, California 5332921 94063
Site Public Contact
877-642-4691
Richmond 5387428, California 5332921 94801
Rocklin 5388319, California 5332921 95765
Rohnert Park 5388564, California 5332921 94928
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95678
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95823
Sacramento 5389489, California 5332921 95823
San Diego 5391811, California 5332921 92120
San Francisco 5391959, California 5332921 94115
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
Santa Rosa 5393287, California 5332921 95403
Santa Rosa 5393287, California 5332921 95403
South San Francisco 5397765, California 5332921 94080
South San Francisco 5397765, California 5332921 94080
Stockton 5399020, California 5332921 95210
Sunnyvale 5400075, California 5332921 94086
Vacaville 5405228, California 5332921 95688
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Walnut Creek 5406990, California 5332921 94598
Woodland 5410430, California 5332921 95695
Colorado Springs 5417598, Colorado 5417618 80907
Colorado Springs 5417598, Colorado 5417618 80909
Site Public Contact
719-365-2406
Colorado Springs 5417598, Colorado 5417618 80920
Site Public Contact
719-364-6700
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Fort Collins 5577147, Colorado 5417618 80528
Golden 5423294, Colorado 5417618 80401
Greeley 5577592, Colorado 5417618 80631
Loveland 5579368, Colorado 5417618 80538
Site Public Contact
970-203-7083
Jacksonville 4160021, Florida 4155751 32207
Site Public Contact
904-202-7468
Miami 4164138, Florida 4155751 33176
Site Public Contact
786-596-2000
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Augusta 4180531, Georgia 4197000 30912
Boise 5586437, Idaho 5596512 83712
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Twin Falls 5610810, Idaho 5596512 83301
Alton 4232679, Illinois 4896861 62002
Site Public Contact
618-463-7323
Aurora 4883817, Illinois 4896861 60504
Aurora 4883817, Illinois 4896861 60506
Barrington 4884116, Illinois 4896861 60010
Site Public Contact
847-842-4847
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Chicago 4887398, Illinois 4896861 60637
Chicago 4887398, Illinois 4896861 60657
Site Public Contact
773-296-5360
Crystal Lake 4889229, Illinois 4896861 60014
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
Downers Grove 4890119, Illinois 4896861 60515
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Elgin 4890864, Illinois 4896861 60123
Site Public Contact
847-429-2907
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Hazel Crest 4895416, Illinois 4896861 60429
Site Public Contact
708-799-9995
Kewanee 4898433, Illinois 4896861 61443
Libertyville 4899739, Illinois 4896861 60048
Macomb 4900817, Illinois 4896861 61455
Mattoon 4244099, Illinois 4896861 61938
New Lenox 4903535, Illinois 4896861 60451
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Oak Lawn 4904365, Illinois 4896861 60453-2699
Site Public Contact
800-323-8622
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Park Ridge 4905367, Illinois 4896861 60068
Site Public Contact
847-384-3621
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peoria 4905687, Illinois 4896861 61637
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Urbana 4914570, Illinois 4896861 61801
Washington 4915545, Illinois 4896861 61571
Crown Point 4919451, Indiana 4921868 46307
Site Public Contact
219-310-2550
Crown Point 4919451, Indiana 4921868 46307
Dyer 4919820, Indiana 4921868 46311
Site Public Contact
219-924-8178
Hobart 4921476, Indiana 4921868 46342
Site Public Contact
219-947-1795
Hobart 4921476, Indiana 4921868 46342
Munster 4924014, Indiana 4921868 46321
Site Public Contact
219-836-3349
Munster 4924014, Indiana 4921868 46321
Valparaiso 4927537, Indiana 4921868 46383
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-363-2690
Clive 4852065, Iowa 4862182 50325
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Creston 4853078, Iowa 4862182 50801
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Sioux City 4876523, Iowa 4862182 51101
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
West Des Moines 4881346, Iowa 4862182 50266
Kansas City 4273837, Kansas 4273857 66160
Overland Park 4276873, Kansas 4273857 66210
Overland Park 4276873, Kansas 4273857 66211
Westwood 4281639, Kansas 4273857 66205
Wichita 4281730, Kansas 4273857 67214
Lexington 4297983, Kentucky 6254925 40536
Site Public Contact
859-257-3379
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Louisville 4299276, Kentucky 6254925 40241
Louisville 4299276, Kentucky 6254925 40245
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Baltimore 4347778, Maryland 4361885 21201
Site Public Contact
800-888-8823
Columbia 4352053, Maryland 4361885 21044
Site Public Contact
443-546-1300
Glen Burnie 4356188, Maryland 4361885 21061
Site Public Contact
410-553-8100
Ann Arbor 4984247, Michigan 5001836 48106
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Detroit 4990729, Michigan 5001836 48236
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Grosse Pointe Woods 4994871, Michigan 5001836 48236
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49048
Site Public Contact
574-647-7370
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Macomb 5000473, Michigan 5001836 48044
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Saginaw 5007989, Michigan 5001836 48601
Tawas City 5011900, Michigan 5001836 48764
Warren 5014051, Michigan 5001836 48093
Wyoming 5015618, Michigan 5001836 49519
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Burnsville 5019767, Minnesota 5037779 55337
Coon Rapids 5022025, Minnesota 5037779 55433
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Duluth 5024719, Minnesota 5037779 55805
Edina 5025264, Minnesota 5037779 55435
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Maple Grove 5036493, Minnesota 5037779 55369
Maplewood 5036588, Minnesota 5037779 55109
Maplewood 5036588, Minnesota 5037779 55109
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Monticello 5038045, Minnesota 5037779 55362
Robbinsdale 5043439, Minnesota 5037779 55422
Saint Cloud 5044407, Minnesota 5037779 56303
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Sandstone 5045908, Minnesota 5037779 55072
Stillwater 5048814, Minnesota 5037779 55082
Virginia 5051468, Minnesota 5037779 55792
Waconia 5051640, Minnesota 5037779 55387
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Creve Coeur 4382837, Missouri 4398678 63141
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
North Kansas City 4400860, Missouri 4398678 64116
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63136
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Reno 5511077, Nevada 5509151 89502
Lebanon 5088597, New Hampshire 5090174 03756
Englewood 5097672, New Jersey 5101760 07631
Site Public Contact
201-894-3456
Jersey City 5099836, New Jersey 5101760 07302
Livingston 5100572, New Jersey 5101760 07039
Long Branch 5100619, New Jersey 5101760 07740
Neptune City 5101687, New Jersey 5101760 07753
Site Public Contact
732-776-4240
New Brunswick 5101717, New Jersey 5101760 08903
Site Public Contact
732-235-7356
Newark 5101798, New Jersey 5101760 07101
Site Public Contact
732-235-7356
Toms River 4504476, New Jersey 5101760 08755
Canandaigua 5111405, New York 5128638 14424
Site Public Contact
585-396-6161
Dansville 5114492, New York 5128638 14437
Lake Success 5123853, New York 5128638 11042
Site Public Contact
516-734-8896
New York 5128581, New York 5128638 10032
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Chapel Hill 4460162, North Carolina 4482348 27599
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Akron 5145476, Ohio 5165418 44307
Centerville 4508204, Ohio 5165418 45459
Chillicothe 4828890, Ohio 5165418 45601
Cincinnati 4508722, Ohio 5165418 45219
Cincinnati 4508722, Ohio 5165418 45220
Cincinnati 4508722, Ohio 5165418 45242
Cleveland 5150529, Ohio 5165418 44109
Cleveland 5150529, Ohio 5165418 44195
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43214
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Dublin 5152333, Ohio 5165418 43016
Franklin 4512203, Ohio 5165418 45005-1066
Greenville 5156493, Ohio 5165418 45331
Site Public Contact
937-569-7515
Sylvania 5173572, Ohio 5165418 43560
Toledo 5174035, Ohio 5165418 43606
Troy 5174358, Ohio 5165418 45373
West Chester 4520522, Ohio 5165418 45069
Oklahoma City 4544349, Oklahoma 4544379 73104
Tulsa 4553433, Oklahoma 4544379 74146
Site Public Contact
918-505-3200
Gresham 5729485, Oregon 5744337 97030
Site Public Contact
503-413-2150
Newberg 5742726, Oregon 5744337 97132
Portland 5746545, Oregon 5744337 97210
Portland 5746545, Oregon 5744337 97225
Portland 5746545, Oregon 5744337 97227
Tualatin 5757506, Oregon 5744337 97062
Site Public Contact
503-413-1742
Allentown 5178127, Pennsylvania 6254927 18103
Altoona 5178195, Pennsylvania 6254927 16601
Erie 5188843, Pennsylvania 6254927 16505
Farrell 5189377, Pennsylvania 6254927 16121
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Greenville 5192019, Pennsylvania 6254927 16125
Hershey 5193342, Pennsylvania 6254927 17033-0850
Jefferson Hills 5195297, Pennsylvania 6254927 15025
Johnstown 5195561, Pennsylvania 6254927 15901
Site Public Contact
814-534-4724
Monroeville 5201734, Pennsylvania 6254927 15146
Site Public Contact
412-858-7746
Pittsburgh 5206379, Pennsylvania 6254927 15212
Site Public Contact
877-284-2000
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-621-2334
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
West Reading 5218867, Pennsylvania 6254927 19611
Site Public Contact
610-988-9323
Wexford 5219062, Pennsylvania 6254927 15090
Wilkes-Barre 5219488, Pennsylvania 6254927 18711
Charleston 4574324, South Carolina 4597040 29401
Charleston 4574324, South Carolina 4597040 29403
Charleston 4574324, South Carolina 4597040 29414
Charleston 4574324, South Carolina 4597040 29414
Pierre 5767918, South Dakota 5769223 57501
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57105
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Yankton 5233053, South Dakota 5769223 57078
Dallas 4684888, Texas 4736286 75235
Dallas 4684888, Texas 4736286 75390
Houston 4699066, Texas 4736286 77030
Houston 4699066, Texas 4736286 77030
Site Public Contact
713-873-2000
Houston 4699066, Texas 4736286 77030
Site Public Contact
713-792-3245
Humble 4699442, Texas 4736286 77338
The Woodlands 4736476, Texas 4736286 77380
American Fork 5844096, Utah 5549030 84003
Cedar City 5536630, Utah 5549030 84720
Logan 5777544, Utah 5549030 84321
Murray 5778755, Utah 5549030 84107
Ogden 5779206, Utah 5549030 84403
Provo 5780026, Utah 5549030 84604
Riverton 5780557, Utah 5549030 84065
Salt Lake City 5780993, Utah 5549030 84143
St. George 5546220, Utah 5549030 84770
Berlin Corners 5233780, Vermont 5242283 05602
Site Public Contact
802-225-5400
Burlington 5234372, Vermont 5242283 05401
Burlington 5234372, Vermont 5242283 05405
Saint Johnsbury 5240656, Vermont 5242283 05819
Alexandria 4744091, Virginia 6254928 22304
Fairfax 4758023, Virginia 6254928 22031
Fairfax 4758023, Virginia 6254928 22033
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23226
Richmond 4781708, Virginia 6254928 23229
Site Public Contact
804-591-4152
Richmond 4781708, Virginia 6254928 23230
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
Seattle 5809844, Washington 5815135 98101
Vancouver 5814616, Washington 5815135 98684
Vancouver 5814616, Washington 5815135 98686
Site Public Contact
503-413-2150
Morgantown 4815352, West Virginia 4826850 26506
Ashland 5244247, Wisconsin 5279468 54806
Ashland 5244247, Wisconsin 5279468 54806
Burlington 5247214, Wisconsin 5279468 53105
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54301
Green Bay 5254962, Wisconsin 5279468 54311
Hayward 5255882, Wisconsin 5279468 54843
Johnson Creek 5257996, Wisconsin 5279468 53038
Kenosha 5258393, Wisconsin 5279468 53142
La Crosse 5258957, Wisconsin 5279468 54601
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marinette 5261852, Wisconsin 5279468 54143
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53233
Mukwonago 5263965, Wisconsin 5279468 53149
New Richmond 5264475, Wisconsin 5279468 54017
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53406
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Spooner 5274034, Wisconsin 5279468 54801
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Summit, Wisconsin 5279468 53066
Superior 5275191, Wisconsin 5279468 54880
Site Public Contact
701-364-6272
Two Rivers 5276609, Wisconsin 5279468 54241
Waukesha 5278052, Wisconsin 5279468 53188
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
More Details
- NCT ID
- NCT05095376
- Status
- Recruiting
- Sponsor
- NRG Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) significantly prolongs overall survival (OS) versus (vs.) standard chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma (GBM) with MGMT promoter methylation. SECONDARY OBJECTIVES: I. To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) significantly prolongs progression-free survival (PFS) vs. standard chemoradiotherapy with temozolomide in patients with newly diagnosed GBM with MGMT promoter methylation. II. To compare the two different chemotherapy regimens on patient-reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM with MGMT promoter methylation. III. To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) is associated with inferior short-term change in PROs as measured by MDASI-BT vs. standard chemoradiotherapy with temozolomide in patients with newly diagnosed GBM with MGMT promoter methylation. IV. To assess toxicity in the two different chemotherapy regimens. EXPLORATORY OBJECTIVES: I. To assess the association between absolute lymphocyte counts and outcomes. II. To assess the association between CD4+ lymphocyte counts and outcomes. III. To compare the two different chemotherapy regimens in terms of long-term PROs as measured by MDASI-BT at years 1 and 2. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo radiation therapy 5 days per week and receive temozolomide orally (PO) once daily (QD) for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo magnetic resonance imaging (MRI) throughout the trial. ARM II: Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 of each cycle and temozolomide PO QD on days 2-6 of each cycle. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial. After completion of study treatment, patients are followed up every 3 months for year 1, every 4 months for year 2, and then every 6 months thereafter.